Work

Supplementary Table 3 from Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245409 (XL765), a Novel, Orally Administered PI3K/mTOR Inhibitor in Patients with Advanced Solid Tumors

Year: 2023

Type: supplementary-materials

Abstract: PDF file - 89KB, Supplementary Table 3. Reduction in Phosphoinositide 3-kinase and Mammalian Target of Rapamycin Complex 1 (mTORC1)/mTORC2 Pathway Signaling in Paired Tumor Biopsies.

DOI: 10.1158/1078-0432.22448580

Authors: Kyriakos P. Papadopoulos, Josep Tabernero, Ben Markman, Amita Patnaik, Anthony W. Tolcher, José Baselga, Weiliang Shi, Coumaran Egile, Rodrigo Ruiz-Soto, A. Douglas Laird, Dale Miles, Patricia M. LoRusso

Language: English

Topic: PI3K/AKT/mTOR signaling in cancer

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4362394807

Cites:

Cited by:

Related to: 10